S&P Global Offerings
Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
S&P Global Offerings
Featured Topics
Featured Products
Events
Our Methodology
Methodology & Participation
Reference Tools
S&P Global
S&P Global Offerings
S&P Global
Research & Insights
Our Methodology
Methodology & Participation
Reference Tools
S&P Global
S&P Global Offerings
S&P Global
Research & Insights
Learn more about Veterinary Diagnostics Market Analysis
The majority of animal health companies sell drugs for cats and dogs. The largest sub-segment of the animal health industry is the pet antiparasitics space. Other drugs include therapeutics for pain, cancer and allergies.
In recent years, animal health has seen the introduction of multiple blockbuster drugs (over $100 million in annual sales) for cats and dogs.
There is limited generic competition in the animal health sector, meaning brands have significant longevity.
Zoetis made more annual sales in the companion animal sector than the livestock market for the first time in 2019.
Recent new blockbuster pharmaceuticals include Apoquel, Simparica and Cytopoint from Zoetis.
Many pet owners – especially millennials – are becoming increasingly interested in pet health and stimulating the ‘humanization’ of companion animals.
Many animal health companies, from multinationals to start-ups, are focusing on developing new pet drugs. Zoetis has shown recently there is demand for new pet treatments in dermatology and this has stimulated increased research and development in pet health (pain, cancer, allergies, anxiety etc). Spending on pets is increasing in developed markets and China as well. As well as internal R&D, animal health companies are licensing technologies from the human pharma sector and trying to translate this innovation to pets. One key area of innovation is monoclonal antibodies (mAbs). In human pharmaceuticals, most top-selling drugs are mAbs. In animal health, there is only one mAb on sale. Companies such as Zoetis, Kindred Biosciences and PetMedix are now aiming to bring more mAbs to animal health.
At S&P Markit we offer market-leading animal health information solutions via our globally recognised Animal health Market Reporting service powered by Animal Pharm. Our specialist team of experts offer comprehensive news, data and independent analysis across the global industry, with current news, data and market forecasting solutions to support all operational needs in your organisation.
Our Animal Health Market Reporting service is the market leader in updates and news on animal health company developments, emerging trends, mergers and acquisitions, regulatory and competitive changes across the animal health market. Spanning pharmaceuticals, vaccines, diagnostics and technology, a subscription also includes access to a range of tracking tools on M&A, funding, patents and drug approvals.
Published throughout the year these reports dive deeper than information available with an Animal Health Market Reporting service alone, taking special reports on key topics driving the vaccine, antiparasitic and diagnostics markets, complementing our subscription services. These provide critical updates on regulations, products, technology and other emerging trends.
Consulting services spanning all your needs in the animal health markets, from long-term forecasting to market studies for financial investments reviewing everything from market sizing to competitor intelligence.
At S&P Markit we offer market-leading animal health information solutions via our globally recognised Animal health Market Reporting service powered by Animal Pharm. Our specialist team of experts offer comprehensive news, data and independent analysis across the global industry, with current news, data and market forecasting solutions to support all operational needs in your organisation.
Our Animal Health Market Reporting service is the market leader in updates and news on animal health company developments, emerging trends, mergers and acquisitions, regulatory and competitive changes across the animal health market. Spanning pharmaceuticals, vaccines, diagnostics and technology, a subscription also includes access to a range of tracking tools on M&A, funding, patents and drug approvals.
Published throughout the year these reports dive deeper than information available with an Animal Health Market Reporting service alone, taking special reports on key topics driving the vaccine, antiparasitic and diagnostics markets, complementing our subscription services. These provide critical updates on regulations, products, technology and other emerging trends.
Consulting services spanning all your needs in the animal health markets, from long-term forecasting to market studies for financial investments reviewing everything from market sizing to competitor intelligence.
Get the edge in today’s global markets with our Essential Intelligence® delivered through the providers and platforms which suit you.
For 100+ years, we've delivered Platts price assessments for physical and forward markets. Customers count on us for news, pricing, and analytics, ensuring transparent, efficient markets for confident decisions.
With 250+ Platts benchmarks, we're the industry standard for pricing negotiations and contracts. Our proven credibility in market transparency spans established and emerging markets.
Our robust methodology guarantees data integrity with stringent quality controls, diverse sources, and adherence to strict guidelines and IOSCO principles. We openly publish methodologies and price assessments to foster trust.
Gain access to our essential intelligence direct and from multiple providers – from the established to the cutting edge – all via multiple platforms that can give you a decisive edge in today's global markets.
Globally, our extensive pricing experts, dedicated to each commodity ensure that pricing and methodology accuracy and that reflect the nuances and complexities of the markets, offering invaluable insights to clients.
Platts offers an independent and unbiased view. Our commitment to impartiality ensures that our assessments and insights are trusted by market participants.
Interested in this product?
Complete the form and a team member will reach out to discuss how our solutions can support you.